Arndt Benecke

This study evaluates the tolerance and innate immune response of human respiratory epithelial cells to FLAMOD, a flagellin-based therapy, showing dose-dependent activation of immune pathways without tissue damage.

This study shows that nebulized FLAMOD, a flagellin agonist, induces a robust immune response in pigs without adverse effects, highlighting innate immunity and bacterial defense pathways.